Johnson & Johnson Launches Generation Fine After Survey Finds 80% Doubt Remission
Johnson & Johnson launched Generation Fine on May 7, 2026, after a survey in seven countries found nearly 80% of major depressive disorder patients believe antidepressants cannot achieve full remission. The initiative partners with Mental Health America and advocates to offer conversation tools, patient stories and resources aimed at driving treatment adjustments toward remission.
1. Campaign Overview
On May 7, 2026, Johnson & Johnson introduced Generation Fine, a global initiative designed to reshape expectations in depression care by encouraging patients to seek remission rather than settling for feeling "fine."
2. Global Survey Insights
The campaign is informed by a survey of patients and healthcare providers across seven countries and four continents, revealing that nearly 4 in 5 major depressive disorder patients doubt that current antidepressants will achieve full remission.
3. Patient Engagement and Resources
Generation Fine collaborates with Mental Health America and mental health advocates, including retired NFL player Kyle Long, to share authentic patient stories and provide tools and guides that help patients initiate discussions about residual symptoms.
4. Strategic Implications for Johnson & Johnson
By launching Generation Fine, Johnson & Johnson underscores its commitment to neuroscience and mental health care, potentially enhancing its CNS portfolio visibility and supporting future research and product development in depression treatment.